258 related articles for article (PubMed ID: 36993976)
1. A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
Luo Y; Ye Y; Chen Y; Zhang C; Sun Y; Wang C; Ou J
Front Immunol; 2023; 14():1140993. PubMed ID: 36993976
[TBL] [Abstract][Full Text] [Related]
2. Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.
Ye Y; Luo Y; Guo T; Zhang C; Sun Y; Xu A; Ji L; Ou J; Wu SY
Front Endocrinol (Lausanne); 2023; 14():1179050. PubMed ID: 37600707
[TBL] [Abstract][Full Text] [Related]
3. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
Xu X; Wang J
Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
Tang W; Xu F; Zhao M; Zhang S
BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
[TBL] [Abstract][Full Text] [Related]
5. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
6. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
9. Prognosis stratification of patients with breast invasive carcinoma based on cysteine metabolism-disulfidptosis affinity.
Zhang Y; Ye Y; Xu A; Luo Y; Sun Y; Zhang W; Ji L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11979-11994. PubMed ID: 37422541
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
11. Development of a circHIPK3-based ceRNA network and identification of mRNA signature in breast cancer patients harboring BRCA mutation.
Lian QX; Song Y; Han L; Wang Z; Song Y
PeerJ; 2023; 11():e15572. PubMed ID: 37426414
[TBL] [Abstract][Full Text] [Related]
12. Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature.
Shen L; Huang H; Li J; Chen W; Yao Y; Hu J; Zhou J; Huang F; Ni C
Front Immunol; 2023; 14():1199465. PubMed ID: 37469520
[TBL] [Abstract][Full Text] [Related]
13. A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer.
Liu Z; Mi M; Li X; Zheng X; Wu G; Zhang L
J Cell Mol Med; 2020 Nov; 24(21):12444-12456. PubMed ID: 32967061
[TBL] [Abstract][Full Text] [Related]
14. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
15. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive research into prognostic and immune signatures of transcription factor family in breast cancer.
Wu Q; Zheng S; Lin N; Xie X
BMC Med Genomics; 2023 Apr; 16(1):87. PubMed ID: 37098532
[TBL] [Abstract][Full Text] [Related]
17. Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer.
Liu Y; Ouyang W; Huang H; Tan Y; Zhang Z; Yu Y; Yao H
Front Oncol; 2022; 12():960579. PubMed ID: 36713514
[TBL] [Abstract][Full Text] [Related]
18. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
19. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]